Literature DB >> 28432002

miR-429 inhibits metastasis by targeting KIAA0101 in Soft Tissue Sarcoma.

Devyani Samantarrai1, Bibekanand Mallick2.   

Abstract

Soft tissue sarcomas (STS) are a heterogeneous group of rare tumors with high metastatic potential. There being only a handful of publication on metastasis of STS, we investigated the miRNA mediated target gene regulations in modulating the metastatic processes in this cancer. In this study, we amalgamated gene and miRNA expression profiles of high-grade STS samples with miRNA target predictions and identified miR-429 targeting KIAA0101 as a novel pair, which remain unexplored in STS metastasis. We validated their expression in metastatic fibrosarcoma cell line, HT1080 and performed several functional assays using miRNA mimics and KIAA0101 over-expression vector to confirm their role in metastasis. We observed miR-429 is downregulated in HT1080 cells and acting as an anti-metastatic miRNA that inhibited proliferation, migration, anchorage independent growth and invasion by de-repressing KIAA0101. Moreover, the renilla luciferase reporter assay confirmed that miR-429 targets KIAA0101 by binding to its 3/UTR and influence its expression. Taken together, our work demonstrated miR-429 mediates deregulation of KIAA0101 by acting as an anti-metastatic miRNA that targets KIAA0101 pro-metastatic gene during metastasis of STS.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gene regulation; Metastasis; MiR-429; NcRNA; STS

Mesh:

Substances:

Year:  2017        PMID: 28432002     DOI: 10.1016/j.yexcr.2017.04.017

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  [Inhibitory effect of miR-429 on expressions of ZO-1, Occludin, and Claudin-5 proteins to improve the permeability of blood spinal cord barrier in vitro].

Authors:  Rui Sun; Deshui Yu
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-09-15

2.  Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers.

Authors:  Garima Singh; Jyoti Roy; Pratiti Rout; Bibekanand Mallick
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

3.  miR-429 suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma by downregulation of TLN1.

Authors:  Zhihui Wang; Zhiquan Zhu; Zhong Lin; Youli Luo; Zibin Liang; Caibin Zhang; Jianxu Chen; Peijian Peng
Journal:  Cancer Cell Int       Date:  2019-04-30       Impact factor: 5.722

Review 4.  The Role of Noncoding RNAs in the Regulation of Anoikis and Anchorage-Independent Growth in Cancer.

Authors:  Han Yeoung Lee; Seung Wan Son; Sokviseth Moeng; Soo Young Choi; Jong Kook Park
Journal:  Int J Mol Sci       Date:  2021-01-10       Impact factor: 5.923

5.  Targeting Lymphotoxin Beta and Paired Box 5: a potential therapeutic strategy for soft tissue sarcoma metastasis.

Authors:  Runzhi Huang; Zhiwei Zeng; Penghui Yan; Huabin Yin; Xiaolong Zhu; Peng Hu; Juanwei Zhuang; Jiaju Li; Siqi Li; Dianwen Song; Tong Meng; Zongqiang Huang
Journal:  Cancer Cell Int       Date:  2021-01-04       Impact factor: 5.722

Review 6.  Immunomodulatory Properties of Human Breast Milk: MicroRNA Contents and Potential Epigenetic Effects.

Authors:  Ma'mon M Hatmal; Mohammad A I Al-Hatamleh; Amin N Olaimat; Walhan Alshaer; Hanan Hasan; Khaled A Albakri; Enas Alkhafaji; Nada N Issa; Murad A Al-Holy; Salim M Abderrahman; Atiyeh M Abdallah; Rohimah Mohamud
Journal:  Biomedicines       Date:  2022-05-24

7.  miRNA-mediated 'tug-of-war' model reveals ceRNA propensity of genes in cancers.

Authors:  Arpit Chandan Swain; Bibekanand Mallick
Journal:  Mol Oncol       Date:  2018-04-17       Impact factor: 6.603

8.  Circular RNA TADA2A promotes proliferation and migration via modulating of miR‑638/KIAA0101 signal in non‑small cell lung cancer.

Authors:  Ye Zhang; Hongmin Yao; Ying Li; Lu Yang; Liang Zhang; Jinxin Chen; Yong Wang; Xia Li
Journal:  Oncol Rep       Date:  2021-07-23       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.